See today's BioWorld Asia
To read the full story, subscribe or sign in.

Genexine, EPD Biotherapeutics to merge for new protein degraders

July 9, 2024
By Marian (YoonJee) Chu
Seoul, South Korea-based Genexine Co. Ltd. plans to merge with privately held EPD Biotherapeutics Co. Ltd. by October 2024 to build a pipeline of novel targeted protein degradation therapeutics with EPD Bio’s BioPROTAC platform technology.
BioWorld Asia Deals and M&A Cancer Protein Asia-Pacific